
Study 309/Keynote-775: A Randomized, Phase 3 Study to Compare the Efficacy and Safety of Lenvatinib with Pembrolizumab vs Treatment of Physician’s Choice in Advanced Endometrial Cancer
Tuesday, May 10, 2022
8:30 am ET
Website: https://us06web.zoom.us/webinar/register/WN_PqID8VoLQc2Uwppdb9ifCg
- This event has passed.